Dolutegravir demonstrated noninferiority to low-dose efavirenz in antiretroviral (ART)-naïve patients with HIV-1 infection in a resource-limited setting, according to the NAMSAL ANRS 12313* study presented at IAS 2019.
Children born to women receiving dolutegravir-based antiretroviral therapy (ART) for HIV since conception have an uptick of neural-tube defects compared with those whose mothers took non-dolutegravir ART at conception, additional follow-up data from the Tsepamo surveillance study show.
The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.
The investigational first-in-class attachment inhibitor prodrug fostemsavir (FTR) continues to improve virologic and immunologic response from weeks 48 to 96 in patients with multidrug-resistant HIV-1 who had been heavily treated, according to the BRIGHTE* study presented at IAS 2019.
Individuals with HIV-1 who demonstrate virologic suppression on a tenofovir alafenamide fumarate (TAF)-based three- or four-drug regimen (TBR) could safely switch to a two-drug regimen comprising dolutegravir and lamivudine, according to results from the phase III TANGO* study presented at the recent International AIDS Society conference (IAS 2019).
The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.
Persons living with HIV (PLHIV) who received monthly long-acting (LA) intramuscular formulations of the INSTI* cabotegravir and the NNRTI** rilpivirine reported higher levels of treatment satisfaction and treatment acceptance, and greater willingness to continue therapy as opposed to a daily oral antiretroviral therapy (ART) regimen, according to patient-reported outcomes of the ATLAS*** and FLAIR# trials presented at IAS 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Infectious Diseases - Malaysia digital copy today!
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Streptococcus anginosus, aminoglycoside-susceptible Gram-negative bacilli and anaerobes remain the most common bacteria in previously healthy children presenting with complicated appendicitis requiring surgical drainage, reports a study.